MD PhD H.J.G.D. van den Bongard

Medical Specialist
Main activities
Patient care, Research
Radiation oncology; with focus on breast cancer, MR-guided radiotherapy, hyperthermia, oligometastases.
Focus of research

Dr. van den Bongards research is focussed on de-escalation of treatment and decreased treatment-induced morbidity in breast cancer patients with the aim to optimize quality of life after treatment.

Her main focus in research is the clinical introduction of treatment with one single-dose pre-operative MR-guided Partial Breast Irradiation (PBI) in low-risk breast cancer patients (instead of standard post-operative partial or whole breast irradiation during 2 to 5 weeks).

Pre-operative instead of post-operative PBI has the potential to further decrease radiotherapy-induced toxicity and improve quality of life due to irradiation of smaller target volumes and reduced organs at risk volumes. Pre-operative PBI offers the possibility for response monitoring using imaging, and evaluation of response markers in blood and tumor tissue compared to the standard postoperative irradiation. In addition, pre-operative PBI has the potential to greatly reduce the treatment burden if the pathologic complete response can be accurately predicted, and would allow omitting breast-conserving surgery. Moreover, patients that would still require BCS would benefit from a single dose of pre-operative PBI instead of 2 to 5 weeks of postoperative irradiation in the current standard of care. 

The clinical feasibility of pre-operative irradiation with one single dose followed by breast-conserving surgery 6 to 8 month after irradiation has been proven in a multicenter study that showed a pathologic complete response in more than 40% of the patients. In the recent future, the ABLATIVE-2 trial will be initiated to study the response at 1 year after pre-operative PBI including potential response predictors in these patients.



Key publications
  • Vasmel Jeanine E., Charaghvandi Ramona K., Houweling Antonetta C., Philippens Marielle E. P., van Asselen Bram, Vreuls Celien P. H., van Diest Paul J., van Leeuwen A. M. Gijs, van Gorp Joost, Witkamp Arjen J., Koelemij Ron, Doeksen Annemiek, Sier Maartje F., van Dalen Thijs, van der Wall Elsken, van Dam Iris, Veldhuis Wouter B., Kirby Anna M., Verkooijen Helena M., van den Bongard H. J. G. Desiree Tumor Response After Neoadjuvant Magnetic Resonance Guided Single Ablative Dose Partial Breast Irradiation International journal of radiation oncology, biology, physics 2020;106 (4):821-829 [PubMed]
  • Charaghvandi R. K., van Asselen B., Philippens M. E. P., Verkooijen H. M., van Gils C. H., van Diest P. J., Pijnappel R. M., Hobbelink M. G. G., Witkamp A. J., van Dalen T., van der Wall E., van Heijst T. C., Koelemij R., van Vulpen M., van den Bongard H. J. G. D. Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: A study protocol BMC cancer 2017;17 (1) [PubMed]
  • Gregorowitsch Madelijn L., Verkooijen Helena M., Houweling Anette, Fuhler Nick, Koelemij Ron, Schoenmaeckers Ernst J. P., Sier Maartje F., Ernst Miranda F., Witkamp Arjen J., van Dalen Thijs, Young-Afat Danny A., van den Bongard Desiree H. J. G. Impact of modern-day axillary treatment on patient reported arm morbidity and physical functioning in breast cancer patients Radiotherapy and oncology 2019;131:221-228 [PubMed]
  • Gregorowitsch M. L., van den Bongard H. J. G. D., Young-Afat D. A., Pignol J. P., van Gils C. H., May A. M., Verkooijen H. M. Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients Breast cancer research and treatment 2018;167 (1):205-213 [PubMed]
  • Charaghvandi Ramona K., den Hartogh Mariska D., van Ommen Anne-Mar L. N., de Vries Wilfred J. H., Scholten Vincent, Moerland Marinus A., Philippens Mariëlle E. P., Schokker Rogier I., van Vulpen Marco, van Asselen Bram, van den Bongard Desirée H. J. G. MRI-guided single fraction ablative radiotherapy for early-stage breast cancer: A brachytherapy versus volumetric modulated arc therapy dosimetry study Radiotherapy and oncology 2015;117 (3):477-482 [PubMed]
All Publications
Curriculum Vitae

Dr. Desirée van den Bongard is employed as a staff member at the Department of Radiation Oncology at the Amsterdam University Medical Centers, since September 2019. From 2009 to 2019, she was employed as a staff member at the Department of Radiation Oncology at the University medical Center Utrecht. Breast cancer treatment and oligometastatic disease are her main specialties for patient care. The focus of her breast cancer research is de-escalation of breast cancer radiation therapy with the aim to further decrease the burden of breast cancer treatment, treatment-induced toxicity and improve the quality of life after breast cancer treatment. In low-risk breast cancer patients, she introduced one single dose of preoperative ablative radiotherapy (ABLATIVE trial) instead of the standard multiple fractions of postoperative irradiation with an overall treatment time of up to five weeks. Besides the aims to decrease the treatment burden and radiation therapy-induced toxicity, the blue sky is to predict the response after one single radiotherapy dose using deep learning methods artificial intelligence methods. This could lead to omission of breast surgery in selected future low-risk patients with a complete response after one single radiotherapy dose. Other research activities include the implementation of MRI-guided radiotherapy in breast cancer patients instead of standard radiotherapy planning CT only, to enable better definition of the irradiation target volumes, i.e. breast tumor in preoperative radiotherapy, and to minimize the radiotherapy dose in the surrounding normal tissues, such as the contralateral breast, heart and lungs which can result in decreased radiotherapy-induced toxicity and improved quality of life in these patients.


Professional experience and education

9-2019:            Radiation oncologist, Amsterdam UMC. Focus in patient care: Breast cancer, MR-guided radiotherapy, Hyperthermia and re-irradiation. Focus in research: De-escalation of breast cancer treatment, single ablative dose in radiotherapy.

2009-8/2019:   Radiation oncologist, UMC Utrecht. Focus in patient care: Breast cancer, MR-guided radiotherapy, Oligometastatic disease. Focus in research: De-escalation of breast cancer treatment, single ablative dose in radiotherapy.

2003-2008:      Radiation oncologist in training - Antoni van Leeuwenhoek ziekenhuis, Amsterdam.

2002-2003:      Internal Medicine, in training - UMC Utrecht

2002:               PhD, Utrecht University. Title dissertation: Clinical pharmacokinetics of anticancer drugs

1999-2002:      PhD student - Antoni van Leeuwenhoek hospital/Netherlands Cancer Institute, Amsterdam

1998-1999:      Resident in Medical Oncology - Antoni van Leeuwenhoek hospital/Netherlands Cancer Institute, Amsterdam

1998:               MD, Maastricht University

1995:               Research internship: Departments of Physiology and Pediatrics - University Southwestern Medical School, Dallas, Texas, USA


Professional and teaching activities

Since 2013:     Faculty ESTRO teaching course Advanced Treatment Planning

Since 2015:     Reviewer for a range of journals including Radiotherapy and Oncology, the Breast, International Journal of Oncology Radiation Biology Physics, Clinical Breast Cancer, PLOS one

Since 2016:     Member Working Group Dutch Guidelines Breast cancer

Since 2016:     Chair Dutch Platform Radiotherapy Breast Cancer

Since 2018:     Member Editorial Office Blad B Dutch Breast Cancer Society

2013-2019:      Board IKNL-tumor working group Mammacarcinoom regio Utrecht

2013-2019:      Member Tumor Site Group Breast in the Atlantic Consortium MR-linac

2017-2019:      Member expertcommittee Shared Decision Making UMC Utrecht

2012-2016:      Member Scientific Advisory Committee - Pink Ribbon

2014-2016:      Teacher Clinical Scientific Education for Medical students, UMC Utrecht

2011-2017:      Teacher MRI course in Radiotherapy - UMC Utrecht

2012-2017:      Teacher Summer School, UMC Utrecht



2018:               Beslist Samen-2 grant: Shared Decision making in the Breast Cancer multidisciplinary meeting - UMC Utrecht in collaboration with Borstkanker Vereniging Nederland and Maastricht UMC+ (Role: PI)

2013:               KWF/Pink Ribbon Foundation research grant: Towards a single ablative radiation treatment in elderly breast cancer patients (Role: PI)

2006:               Scholarship FECS-AACR-ASCO: Methods in Clinical Cancer Research (Flims, Switzerland)



2018-2019:     Leadership programme Steyn Parve – UMC Utrecht

2016:              The informal leader, De Baak


Clinical trial activities/Principal investigator:

ABLATIVE-2 trial: MRI-guided single dose preoperative radiotherapy in low-risk breast cancer patients (NL63209.041.18)

ABLATIVE trial: Single ablative dose radiotherapy in breast cancer patients (NL 46017.041.13, identifier: NCT02316561)

MILANO trial: MR-imaging before and after sentinel lymph node biopsy in breast cancer patients (NL 46017.041.13)

MAMRICT trial: MR-imaging before and after breast-conserving surgery (NTR3198)



BRAGATSTON trial: A multicentre cohort study on automated quantification of cardiovascular calcifications on radiotherapy planning CT scans for cardiovascular risk prediction in patients with breast cancer (NCT03206333)

UMBRELLA FIT trial: The effects of exercise on the quality of life of patients with breast cancer: study protocol for a randomized controlled trial (NTR5482/NL.52062.041.15)

UMBRELLA study group: Utrecht cohort for multiple beast cancer intervention studies and long-team evaluation (NCT02839863)


PhD Supervisorships:

1. Madelijn Gregowitsch, MD PhD. Patient-reported outcomes after breast cancer treatment. 

PhD defence: December 17, 2019. Utrecht University. 

2. Ramona Charaghvandi, MD PhD. Treatment de-escalation for early-stage breast cancer.

PhD defence: June 18, 2019. Utrecht University.

3. Danny Young Afat, MD PhD: Innovations in Patient-centered breast cancer research.

PhD defence: December 18, 2018. Utrecht University.

4. Sofie Gernaat, PhD: Cardiovascular disease after breast cancer treatment.

PhD defence: February 23, 2018. Utrecht University.

5. Tristan van Heijst, PhD. Towards breast cancer radiotherapy on the MRI-linac.

PhD defence: January 12, 2017. Utrecht University.

6. Mariska den Hartogh, MD PhD. Towards MRI-guided radiotherapy in early-stage breast cancer patients.

PhD defence: December 18, 2014. Utrecht University.



  1. Vasmel JE, Groot Koerkamp ML, Kirby AM, Russell NS, Shaitelman SF, Vesprini D, Anandadas CN, Currey A, Keller BM, Braunstein LZ, Han K, Koote AN, de Waard SN, Philippens ME, Houweling AC, Verkooijen HM, van den Bongard HD. Consensus on contouring primary breast tumors on MRI in the setting of neoadjuvant partial breast irradiation in trials. Pract Radiat Oncol 2020 Apr 18. Pii: S1879-8500(2)30092-8. Doi: 10.1016/j.prro.2020.03.01 PMID: 32315784.
  2. Raphael DB, Russell NS, Immink JM, Wethoff PG, Stenfert Kroese MC, Stam MR, van Maurik LM, van den Bongard HJGD, Maduro JH, Sattler MGA, van der Weijden T, Boersma LJ. Risk communication in a patient decision aid for radiotherapy in breast cancer: How to deal with uncertainty? Breast 2020 Apr 6;51:105-113. Doi:10.1016/j.breast.2020.04.001. PMID: 32298961.
  3. Van Velzen SGM, Lessmann N, Velthuis BK, Bank IEM, van den Bongard DHJG, Leiner T, de Jong PA, Veldhuis WB, Correa A, Terry JG, Carr JJ, Viergever MA, Verkooijen HM, Isgum I. Deep Learning for Automatic Calcium Scoring in CT Validation using multiple cardiac CT and Chest CT Protocols. Radiology 2020 Apr;295(1):66-79. Doi:10.1148/radiol.2020191621.
  4. Van de Ven S, van den Bongard D, Pielkenrood B, Kasperts N, Eppinga W, Peters M, Verkooijen H, van der Velden J. Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):39-47. Doi: 10.1016/j.ijrobp.2019.12.041. PMID 32007565.
  5. Reinders FCJ, Young-Afat DA, Batenburg MCT, Bruekers SE, van Amerongen EA, Macaré van Maurik JFM, Braakenburg A, Zonnevylle E, Hoefkens M, Teunis T,Verkooijen HM, van den Bongard HJGD, Maarse W. Higher reconstruction failure and less patient-reported satisfaction after post mastectomy radiotherapy with immediate implant-based breast reconstruction compared to immediate autologous breast reconstruction. Breast Cancer. 2019 Dec 19. doi:10.1007/s12282-019-01036-4. [Epub ahead of print] PubMed PMID: 3185843
  6. Vasmel JE, Charaghvandi RK, Houweling AC, Philippens ME, van Asselen B, Vreuls CP, van Diest PJ, van Leeuwen AG, van Gorp J, Witkamp AJ, Koelemij R, Doeksen A, Sier MF, van Dalen T, van der Wall E, van Dam I, Veldhuis WB, Kirby AM,Verkooijen HM, van den Bongard HD. Tumor response following neoadjuvant MR-guided single ablative dose partial breast irradiation. Int J Radiat Oncol Biol Phys. 2019 Dec 5. pii: S0360-3016(19)34465-7. doi: 10.1016/j.ijrobp.2019.11.40 [Epub ahead of print] PubMed PMID: 31812720.
  7. Batenburg MCT, Gregorowitsch ML, Maarse W, Witkamp A, Young-Afat DA, Braakenburg A, Doeksen A, van Dalen T, Sier M, Schoenmaeckers EJP, van Gils CH, van den Bongard HJGD, Verkooijen HM; UMBRELLA study group. Patient-reported cosmetic satisfaction and the long-term association with quality of life in irradiated breast cancer patients. Breast Cancer Res Treat. 2019 Oct 24. doi: 10.1007/s10549-019-05470-y. [Epub ahead of print] PubMed PMID: 3165034
  8. Gregorowitsch ML, van den Bongard HJGD, Couwenberg AM, Young-Afat DA, Haaring C, Van Dalen T, Schoenmaeckers EJP, Agterof MJ, Baas IO, Sier MF, Ernst MF, vanHummel R, Verkooijen HM; UMBRELLA study group. Self-reported work ability in breast cancer survivors; a prospective cohort study in the Netherlands. Breast. 2019 Dec;48:45-53. doi: 10.1016/j.breast.2019.0004. Epub 2019 Aug 28. PubMed PMID: 31493582.
  9. Young-Afat DA, Gregorowitsch ML, van den Bongard DH, Burgmans I, van der Pol CC, Witkamp AJ, Bijlsma RM, Koelemij R, Schoenmaeckers EJ, Jonasse Y, van Gils CH, Verkooijen HM. Breast Edema Following Breast-Conserving Surgery and Radiotherapy: Patient-Reported Prevalence, Determinants, and Effect on Health-Related Quality of Life. JNCI Cancer Spectr. 2019 Apr 16;3(2):pkz011. doi: 10.1093/jncics/pkz011. eCollection 2019 Jun. PubMed PMID: 31360894; PubMed Central PMCID: PMC6649691.
  10. Emaus MJ, Išgum I, van Velzen SGM, van den Bongard HJGD, Gernaat SAM, Lessmann N, Sattler MGA, Teske AJ, Penninkhof J, Meijer H, Pignol JP, Verkooijen HM; Bragatston study group. Bragatston study protocol: a multicentre cohort study on automated quantification of cardiovascular calcifications on radiotherapy planning CT scans for cardiovascular risk prediction in patients with breast cancer. BMJ Open. 2019 Jul 27;9(7):e028752. doi: 1136/bmjopen-2018-028752. PubMed PMID: 31352417; PubMed Central PMCID: PMC6661654.
  11. Gregorowitsch ML, Van den Bongard DHJG, Batenburg MCT, Traa-van de Grootevheen MJC, Fuhler N, van Het Westeinde T, van der Pol CC, Young-Afat DA, Verkooijen HM. Compression Vest Treatment for Symptomatic Breast Edema in Women Treated for Breast Cancer: A Pilot Study. Lymphat Res Biol. 2019 Jun 18. doi: 10.1089/lrb.2018.0067. [Epub ahead of print] PubMed PMID: 31211631.
  12. Buddeke J, Gernaat SAM, Bots ML, van den Bongard DHJG, Grobbee DE, Vaartjes I, Verkooijen HM. Trends in the risk of cardiovascular disease in women with breast cancer in a Dutch nationwide cohort study. BMJ Open. 2019 May 30;9(5):e022664. doi: 10.1136/bmjopen-2018-022664. PubMed PMID: 31152022; PubMed Central PMCID: PMC6549609.
  13. Gal R, Monninkhof EM, van Gils CH, Groenwold RHH, van den Bongard DHJG, Peeters PHM, Verkooijen HM, May AM. The Trials within Cohorts design faced methodological advantages and disadvantages in the exercise oncology setting. J Clin Epidemiol. 2019 Sep;113:137-146. doi: 10.1016/j.jclinepi.2019.05.017. Epub 2019 May 28. PubMed PMID: 31146022.
  14. Gregorowitsch ML, Ghedri A, Young-Afat DA, Bijlsma R, Baas IO, van Schaik-van de Mheen C, Agterof MJ, Göker E, Ten Bokkel Huinink D, van den Bongard HJGD, Verkooijen HM; UMBRELLA study group. The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients. Breast Cancer Res Treat. 2019 Jun;175(2):429-441. doi: 10.1007/s10549-019-05149-4. Epub 2019 Feb 12. PubMed PMID: 30746636; PubMed Central PMCID: PMC6533221.
  15. Gal R, Monninkhof EM, Peeters PHM, van Gils CH, van den Bongard DHJG,Wendel-Vos GCW, Zuithoff NPA, Verkooijen HM, May AM. Physical activity levels of women with breast cancer during and after treatment, a comparison with the Dutch female population. Acta Oncol. 2019 May;58(5):673-681. doi:10.1080/0284186X.2018.1563712. Epub 2019 Feb 6. PubMed PMID: 30724657.
  16. Charaghvandi KR, Van't Westeinde T, Yoo S, Houweling AC, Rodrigues A, Verkooijen HM, Philippens MEP, van Asselen B, Horton JK, van den Bongard HJGD. Single dose partial breast irradiation using an MRI linear accelerator in the supine and prone treatment position. Clin Transl Radiat Oncol. 2018 Sep 5;14:1-7. doi: 10.1016/j.ctro.2018.09.001. eCollection 2019 Jan. PubMed PMID: 30406210; PubMed Central PMCID: PMC6215022.
  17. Gregorowitsch ML, Verkooijen HM, Houweling A, Fuhler N, Koelemij R, Schoenmaeckers EJP, Sier MF, Ernst MF, Witkamp AJ, Van Dalen T, Young-Afat DA,van den Bongard DHJG; UMBRELLA study group. Impact of modern-day axillary treatment on patient reported arm morbidity and physical functioning in breast cancer patients. Radiother Oncol. 2019 Feb;131:221-228. doi:10.1016/j.radonc.2018.07.006. Epub 2018 Jul 19. PubMed PMID: 30033384.
  18. Gernaat SAM, van Velzen SGM, Koh V, Emaus MJ, Išgum I, Lessmann N, Moes S, Jacobson A, Tan PW, Grobbee DE, van den Bongard DHJ, Tang JI, Verkooijen HM. Automatic quantification of calcifications in the coronary arteries and thoracic aorta on radiotherapy planning CT scans of Western and Asian breast cancer patients. Radiother Oncol. 2018 Jun;127(3):487-492. doi:10.1016/j.radonc.2004.011. Epub 2018 Apr 24. PubMed PMID: 29703498.
  19. Charaghvandi RK, Yoo S, van Asselen B, Rodrigues A, van den Bongard DHJG, Horton JK. Treatment constraints for single dose external beam preoperative partial breast irradiation in early-stage breast cancer. Clin Transl Radiat Oncol. 2017 Sep 8;6:7-14. doi: 10.1016/j.ctro.2017.06.003. eCollection 2017 Oct. PubMed PMID: 29594217; PubMed Central PMCID: PMC5862640.
  20. Gernaat SAM, Boer JMA, van den Bongard DHJ, Maas AHEM, van der Pol CC, Bijlsma RM, Grobbee DE, Verkooijen HM, Peeters PH. The risk of cardiovascular disease following breast cancer by Framingham risk score. Breast Cancer Res Treat. 2018 Jul;170(1):119-127. doi: 10.1007/s10549-018-4723-0. Epub 2018 Feb 28. PubMed PMID: 29492735; PubMed Central PMCID: PMC5993849.
  21. Gal R, Monninkhof EM, Groenwold RHH, van Gils CH, van den Bongard DHJG, Peeters PHM, Verkooijen HM, May AM. The effects of exercise on the quality of life of patients with breast cancer (the UMBRELLA Fit study): study protocol for a randomized controlled trial. Trials. 2017 Oct 27;18(1):504. doi:10.1186/s13063-017-2252-5. PubMed PMID: 29078800; PubMed Central PMCID: PMC5659016.
  22. Gregorowitsch ML, van den Bongard HJGD, Young-Afat DA, Pignol JP, van Gils CH, May AM, Verkooijen HM. Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients. Breast Cancer Res Treat. 2018 Jan;167(1):205-213. doi: 10.1007/s10549-017-4495-y. Epub 2017 Sep 11. PubMed PMID: 28894982.
  23. van Heijst TCF, Eschbach-Zandbergen D, Hoekstra N, van Asselen B, Lagendijk JJW, Verkooijen HM, Pijnappel RM, de Waard SN, Witkamp AJ, van Dalen T, van den Bongard HJGD, Philippens MEP. Supine MRI for regional breast radiotherapy: imaging axillary lymph nodes before and after sentinel-node biopsy. Phys Med Biol. 2017 Aug 1;62(16):6746-6761. doi: 10.1088/1361-6560/aa759f. PubMed PMID: 28556781.
  24. Young-Afat DA, van Gils CH, van den Bongard HJGD, Verkooijen HM; UMBRELLA Study Group. The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results. Breast Cancer Res Treat. 2017 Jul;164(2):445-450. doi: 10.1007/s10549-017-4242-4. Epub 2017 Apr 25. PubMed PMID: 28444532; PubMed Central PMCID: PMC5487711.
  25. Young-Afat DA, van Gils CH, Bruinvels DJ, van der Pol CC, Witkamp AJ, Sijtsema S, Jonasse Y, Bijlsma RM, Ausems MG, Bos AM, van den Bongard DH, Verkooijen HM. Patients' and Health Care Providers' Opinions on a Supportive Health App During Breast Cancer Treatment: A Qualitative Evaluation. JMIR Cancer. 2016 Jun 7;2(1):e8. doi: 10.2196/cancer.5334. PubMed PMID: 28410170; PubMed Central PMCID: PMC5369627.
  26. Rijkmans EC, Cats A, Nout RA, van den Bongard DHJG, Ketelaars M, Buijsen J, Rozema T, Franssen JH, Velema LA, van Triest B, Marijnen CAM. Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study. Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):908-917. doi:10.1016/j.ijrobp.2017.01.033. Epub 2017 Jan 20. PubMed PMID: 28366579.
  27. Middelburg JG, Mast ME, de Kroon M, Jobsen JJ, Rozema T, Maas H, Baartman EA, Geijsen D, van der Leest AH, van den Bongard DJ, van Loon J, Budiharto T, Coebergh JW, Aarts MJ, Struikmans H; LPRO (Dutch National Organization for Radiotherapy in the Elderly). Timed Get Up and Go Test and Geriatric 8 Scores and the Association With (Chemo-)Radiation Therapy Noncompliance and Acute Toxicity in Elderly Cancer Patients. Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):843-849.  doi:10.1016/j.ijrobp.2017.01.211. Epub 2017 Jan 29. PubMed PMID: 28366575.
  28. Knuttel FM, van den Bosch MA, Young-Afat DA, Emaus MJ, van den Bongard DH, Witkamp AJ, Verkooijen HM. Patient Preferences for Minimally Invasive and Open Locoregional Treatment for Early-Stage Breast Cancer. Value Health. 2017 Mar;20(3):474-480. doi: 10.1016/j.jval.2016.10.013. Epub 2016 Dec 22. PubMed PMID: 28292493.
  29. Charaghvandi RK, van Asselen B, Philippens ME, Verkooijen HM, van Gils CH,van Diest PJ, Pijnappel RM, Hobbelink MG, Witkamp AJ, van Dalen T, van der Wall E, van Heijst TC, Koelemij R, van Vulpen M, van den Bongard HJ. Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol. BMC Cancer. 2017 Mar 9;17(1):181. doi: 10.1186/s12885-017-3144-5. PubMed PMID: 28274211; PubMed Central PMCID: PMC5343419.
  30. Gernaat SA, Išgum I, de Vos BD, Takx RA, Young-Afat DA, Rijnberg N, Grobbee DE, van der Graaf Y, de Jong PA, Leiner T, van den Bongard DH, Pignol JP, Verkooijen HM. Automatic Coronary Artery Calcium Scoring on Radiotherapy Planning CT Scans of Breast Cancer Patients: Reproducibility and Association with Traditional Cardiovascular Risk Factors. PLoS One. 2016 Dec 9;11(12):e0167925. doi: 10.1371/journal.pone.0167925. eCollection 2016. PubMed PMID: 27936125; PubMed Central PMCID: PMC5148008.
  31. van Heijst TC, van Asselen B, Pijnappel RM, Cloos-van Balen M, Lagendijk JJ,  van den Bongard D, Philippens ME. MRI sequences for the detection of individual lymph nodes in regional breast radiotherapy planning. Br J Radiol. 2016 Jul;89(1063):20160072. doi: 10.1259/bjr.20160072. Epub 2016 May 10. PubMed PMID: 27164032; PubMed Central PMCID: PMC5257320.
  32. de Boer HC, van den Bongard DJ, van Asselen B. Automated daily breath hold stability measurements by real-time imaging in radiotherapy of breast cancer. Radiother Oncol. 2016 Apr;119(1):61-4. doi:10.1016/j.radonc.2016.02.012. Epub 2016 Feb 16. PubMed PMID: 26900093.
  33. van Heijst TC, Philippens ME, Charaghvandi RK, den Hartogh MD, Lagendijk JJ, van den Bongard HJ, van Asselen B. Quantification of intra-fraction motion in breast radiotherapy using supine magnetic resonance imaging. Phys Med Biol. 2016 Feb 7;61(3):1352-70. PubMed PMID: 26797074.
  34. den Hartogh MD, Philippens ME, VAN Dam IE, Kleynen CE, Tersteeg RJ, Kotte AN, van Vulpen M, van Asselen B, van den Bongard DH. Post-lumpectomy CT-guided tumor bed delineation for breast boost and partial breast irradiation: Can additional pre- and postoperative imaging reduce interobserver variability? Oncol Lett. 2015 Nov;10(5):2795-2801. Epub 2015 Sep 14. PubMed PMID: 26722244; PubMed Central PMCID: PMC4665376.
  35. Charaghvandi RK, den Hartogh MD, van Ommen AM, de Vries WJ, Scholten V, Moerland MA, Philippens ME, Schokker RI, van Vulpen M, van Asselen B, van den Bongard DH. MRI-guided single fraction ablative radiotherapy for early-stage breast cancer: a brachytherapy versus volumetric modulated arc therapy dosimetry study. Radiother Oncol. 2015 Dec;117(3):477-82. doi: 10.1016/j.radonc.2015.09.023. Epub 2015 Oct 1. PubMed PMID: 26438972.
  36. van der Heiden-van der Loo M, de Munck L, Sonke GS, van Dalen T, van Diest, PJ, van den Bongard HJ, Peeters PH, Rutgers EJ. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment. Eur J Cancer. 2015 May;51(8):915-21. doi: 10.1016/j.ejca.2015.03.014. Epub 2015 Apr 6. PubMed PMID: 25857549.
  37. van der Leij F, Bosma SC, van de Vijver MJ, Wesseling J, Vreeswijk S, Rivera S, Bourgier C, Garbay JR, Foukakis T, Lekberg T, van den Bongard DH, van Vliet-Vroegindeweij C, Bartelink H, Rutgers EJ, Elkhuizen PH. First results of the preoperative accelerated partial breast irradiation (PAPBI) trial. Radiother Oncol. 2015 Mar;114(3):322-7. doi:10.1016/j.radonc.2015.02.002. Epub 2015 Feb 17. PubMed PMID: 25701298.
  38. den Hartogh MD, van den Bongard HJ, Davidson MT, Kotte AN, Verkooijen HM, Philippens ME, van Vulpen M, van Asselen B, Pignol JP. Full-thickness closure in breast-conserving surgery: the impact on radiotherapy target definition for boost and partial breast irradiation. A multimodality image evaluation. Ann Surg Oncol.2014 Nov;21(12):3774-9. doi: 10.1245/s10434-014-3801-8. Epub 2014 May 30. PubMed PMID: 24874499.
  39. den Hartogh MD, Philippens ME, van Dam IE, Kleynen CE, Tersteeg RJ, Pijnappel RM, Kotte AN, Verkooijen HM, van den Bosch MA, van Vulpen M, van Asselen B, van den Bongard HD. MRI and CT imaging for preoperative target volume delineation in breast-conserving therapy. Radiat Oncol. 2014 Feb 26;9:63. doi: 10.1186/1748-717X-9-63. PubMed PMID: 24571783; PubMed Central PMCID: PMC3942765.
  40. van Heijst TC, den Hartogh MD, Lagendijk JJ, van den Bongard HJ, van Asselen B. MR-guided breast radiotherapy: feasibility and magnetic-field impact on skin dose. Phys Med Biol. 2013 Sep 7;58(17):5917-30. doi: 10.1088/0031-9155/58/17/5917. Epub 2013 Aug 6. PubMed PMID: 23920343.
  41. Merckel LG, Bartels LW, Köhler MO, van den Bongard HJ, Deckers R, Mali WP, Binkert CA, Moonen CT, Gilhuijs KG, van den Bosch MA. MR-guided high-intensity focused ultrasound ablation of breast cancer with a dedicated breast platform. Cardiovasc Intervent Radiol. 2013 Apr;36(2):292-301. doi: 10.1007/s00270-012-0526-6. Epub 2012 Dec 12. Review. PubMed PMID: 23232856.
  42. Postma EL, van Wieringen S, Hobbelink MG, Verkooijen HM, van den Bongard HJ, Borel Rinkes IH, Witkamp AJ. Sentinel lymph node biopsy of the internal mammary chain in breast cancer. Breast Cancer Res Treat. 2012 Jul;134(2):735-41. doi: 10.1007/s10549-012-2086-5. Epub 2012 Jun 8. PubMed PMID: 22678155; PubMed Central PMCID: PMC3401492.
  43. den Hartogh MD, van Asselen B, Monninkhof EM, van den Bosch MA, van Vulpen M, van Diest PJ, Gilhuijs KG, Witkamp AJ, van de Bunt L, Mali WP, van den Bongard HJ. Excised and irradiated volumes in relation to the tumor size in breast-conserving therapy. Breast Cancer Res Treat. 2011 Oct;129(3):857-65. doi: 10.1007/s10549-011-1696-7. Epub 2011 Aug 6. PubMed PMID: 21822639.
  44. Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, Beijnen JH. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006 Jul;62(1):71-80. PubMed PMID: 16842380; PubMed Central PMCID: PMC1885068.
  45. Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2150-7. PubMed PMID: 16609028.
  46. Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JH. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res. 2004 Jun 1;10(11):3717-27. PubMed PMID: 15173078.
  47. de Jonge ME, van den Bongard HJ, Huitema AD, Mathôt RA, Rosing H, Baas P, van Zandwijk N, Beijnen JH, Schellens JH. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res. 2004 Apr 1;10(7):2237-44. PubMed PMID: 15073098.
  48. van den Bongard HJ, Sparidans RW, Critchley DJ, Beijnen JH, Schellens JH. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. Invest New Drugs. 2004 Apr;22(2):151-8. PubMed PMID: 14739663.
  49. van den Bongard HJ, Kemper EM, van Tellingen O, Rosing H, Mathôt RA, Schellens JH, Beijnen JH. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. Anal Biochem. 2004 Jan 1;324(1):11-5. PubMed PMID: 14654039.
  50. van den Bongard HJ, Mathôt RA, van Tellingen O, Schellens JH, Beijnen JH. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. Cancer Chemother Pharmacol. 2002 Jul;50(1):16-24. Epub 2002 May 1. PubMed PMID: 12111107.
  51. van den Bongard HJ, Boot H, Baas P, Taal BG. The role of parallel stent insertion in patients with esophagorespiratory fistulas. Gastrointest Endosc. 2002 Jan;55(1):110-5. PubMed PMID: 11756930.
  52. van den Bongard HJ, Mathĵt RA, Boogerd W, Schornagel JH, Soesan M, Schellens JH, Beijnen JH. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. Cancer Chemother Pharmacol. 2001 Jun;47(6):537-40. PubMed PMID: 11459208.
  53. Crul M, van den Bongard HJ, Tibben MM, van Tellingen O, Sava G, Schellens JH, Beijnen JH. Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem. 2001 Mar 1;369(5):442-5. PubMed PMID: 11270226.
  54. van den Bongard HJ, Mathôt RA, Beijnen JH, Schellens JH. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet. 2000 Nov;39(5):345-67. Review. PubMed PMID: 11108434